Stability of Butorphanol–Tropisetron Mixtures in 0.9% Sodium Chloride Injection for Patient-Controlled Analgesia Use

Fu-Chao Chen, MD, Xiao-Ya Shi, MD, Peng Li, PhD, Jin-Guo Yang, PhD, and Ben-Hong Zhou, PhD

INTRODUCTION

Drug treatment plays a major role in postoperative pain management. The required medicines are commonly delivered as a patient-controlled analgesia (PCA) with a number of drugs mixed together in a small volume and delivered by a syringe driver. Potential problems of mixing 2 or more injections together in infusion solutions include physical, chemical, or both changes that cause precipitation/crystallization and therefore reduce efficacy.1,2

Butorphanol tartrate is a morphinan-type synthetic opioid analgesic and is a μ-2-receptor antagonist, a μ-1 agonist/antagonist, and a σ- and κ-receptor agonist. Similar to other opioid analgesics, the common adverse effects such as nausea and/or vomiting, somnolence, and dizziness are considerations with butorphanol.3,4 Continuous intravenous administration of butorphanol has been proposed since the 1980s.5 The drug may increase the incidence of postoperative nausea and vomiting (PONV),6 which leads to discontinued administration. Thus, adjuvant medications are widely used to prevent PONV. One adjuvant is tropisetron hydrochloride, which is a selective antagonist of serotonin type 3 receptors (5-HT3).7,8 Previous reports have suggested that adding tropisetron hydrochloride to PCA butorphanol tartrate for postoperative pain produces favorable analgesic effects and decreases the incidence of PONV.9,10 In addition, the solution of butorphanol/tropisetron has been used for postoperative patients in our institution. However, the admixture of butorphanol tartrate and tropisetron hydrochloride for PCA use is not available commercially. An advance preparation of an admixture could improve security, time management, and speed of drug delivery to the hospital floor prior to administration. There is currently no information regarding the chemical stability and compatibility of the butorphanol–tropisetron mixture. Thus, the objective of the current study was to determine the compatibility and stability of the 2 drugs prepared with 0.9% sodium chloride injection and stored in polyolefin bags and glass bottles for a period of 14 days at 4°C and 25°C.

METHODS AND MATERIALS

Sample Preparation

Commercially available ampoules of butorphanol tartrate injection (1 mg/1 mL, lot number 13090432, Hengrui Medicine Co Ltd, Jiangsu, China, containing citric acid, sodium citrate,
sodium chloride, and benzethonium chloride for injection) and tropisetron hydrochloride injection (5 mg/5 mL, lot number 130101, CommScope Pharmaceutical Co Ltd, Hunan, China, containing sodium acetate, acetic acid, sodium chloride, and water for injection) were added to empty 100-mL polyolefin bags (Kelun Pharmaceutical Co, Sichuang, China) or glass bottles (Shangdong Pharmaceutical Glass Co Ltd, Shangdong, China). Then, 0.9% sodium chloride injection solution (Kelun Pharmaceutical Co, lot number A130604) was added to each container to produce a total volume of 100 mL. A rotary shaker was used to agitate the solution after each addition of fluid. The solutions were prepared using aseptic technique in a laminar airflow hood. The final concentrations of butorphanol tartrate and tropisetron hydrochloride were 0.08 and 0.05 mg/mL, respectively. These concentrations corresponded to those used in daily practice. This study was approved by the Medical Ethics Committee of the Dongfeng Hospital, Hubei University of Medicine (MEC-2013-015).

Stability Study of the Analgesic Solutions

Three polyolefin and 3 glass containers containing the butorphanol tartrate and tropisetron hydrochloride admixture were stored in the dark at 4°C and 25°C. A 2-mL sample from each container was removed initially and at 1, 2, 3, 5, 7, 10, and 14 days after mixing. At each time point, the solutions were examined for color, cloudiness, precipitation, and gas production. The pH values for the samples at each designated time interval were determined using a pH meter (Model pHS-3C, Leici Instrument Co, Shanghai, China). All samples were then frozen at −20°C until analysis. The samples were allowed to reach room temperature before injection into the high-pressure liquid chromatography (HPLC) system. Each sample was assayed in triplicate.

HPLC Assay

The HPLC instrumentation consisted of an UltiMate 3000 quaternary gradient pump equipped with a 20-μL autosampler, and a diode-array detector (Dionex, Sunnyvale, CA). The HPLC data were acquired using chromatography management software (Chromelcon, version 6.80, Dionex, Voisins-le-Bretonneux, France). HPLC separation was performed on a Zorbax Hypersil ODS analytical column (150 × 4.6 mm, 5.0 μm, Agilent Technologies, Shanghai Branch, China). The detection of butorphanol tartrate and tropisetron hydrochloride was performed at a wavelength of 280 nm. All samples were assayed at ambient temperature. The mobile phase consisted of 0.05 mol/L potassium dihydrogen phosphate KH₂PO₄ (Nanjing Chemical Reagent Co Ltd, Nanjing, China) and acetonitrile (HPLC grade, Agilent Technologies) in a ratio of 75:25 (v/v). The flow rate was 1.0 mL/min.

The analytical reference standards for butorphanol tartrate and tropisetron hydrochloride were obtained from the National Institutes for Food and Drug Control. The stock standard solutions of butorphanol tartrate 0.8 mg/mL and tropisetron hydrochloride 0.5 mg/mL were prepared in deionized water and frozen at −20°C. Fresh working standard solutions were prepared by diluting the stock solution with deionized water to the required concentrations before use.

Calibration curves were constructed from a linear plot of peak area versus concentration of the reference standards for butorphanol tartrate (16.0–160.0 μg/mL) and tropisetron hydrochloride (5.0–100.0 μg/mL). Three quality control samples (QCs) of butorphanol tartrate (40.0, 80.0, and 120.0 μg/mL) and tropisetron hydrochloride (25.0, 50.0, and 75.0 μg/mL) were used to calculate the accuracy and intraday and interday precisions. The accuracy and intraday precision were estimated using the recovery value and relative standard deviation (RSD, %), which were calculated from 3 QCs of butorphanol tartrate and tropisetron hydrochloride with 5 determinations per concentration on the same day. The interday precision (5 days) was also estimated as the RSD calculated from 5 replicate mixtures of samples prepared in the same way.

Stability Indication

The stability-indicating capability of the chromatographic method was assessed using partially decomposed solutions of drug. The butorphanol tartrate and tropisetron hydrochloride mixture was degraded by heating at 60°C for 5 hours under acidic (0.1 mol/L hydrochloric acid), basic (0.1 mol/L sodium hydroxide), and 3% hydrogen peroxide conditions. The samples were then assayed to confirm separation of the parent molecule from its degradation products.

Analysis of Data

The data are expressed as mean ± standard deviation (SD). At time zero, the initial concentration of both drugs was designated as 100.0%, and all subsequent concentrations were expressed as a percentage of the initial concentration. The stability was defined as a concentration within 90% to 105% of the initial value. Therefore, a decrease from the mean initial concentration of more than 10% was considered a significant loss of the drug.

RESULTS

Validation of the HPLC Method

A new and simple HPLC method was developed and validated for the simultaneous determination of butorphanol tartrate and tropisetron hydrochloride in PCA solution. We found a linear response for butorphanol tartrate between the peak area and concentration with a correlation coefficient (r) better than 0.9996 (y = 108.3x − 0.64). For tropisetron hydrochloride, the linear regression analysis of the peak area of the drug concentration yielded a correlation coefficient (r) better than 0.9991 (y = −1118x − 4.19). The degradation study results showed that the decomposition products were less than 3% and separated from analytes and did not interfere with the quantification of butorphanol tartrate and tropisetron hydrochloride (Figure 1). The retention times were 8.9 minutes for butorphanol tartrate and 6.4 minutes for tropisetron hydrochloride. As shown in Table 1, the results obtained for the accuracy and the intraday and interday precision of the method were satisfactory for the recovery and RSD (%) values. As shown in this table, the intraday and interday RSD (%) were below 2.5% for both drugs and the recoveries obtained were close to 100%.

Stability of the Analgesic Mixtures

The mixtures assayed can be considered as physically compatible because we did not observe evidence of incompatibility such as precipitation, turbidity, color change, opacity, and gas production. Tables 2 and 3 show the percentages of dose remaining for butorphanol tartrate and tropisetron hydrochloride in the admixtures when the tests were conducted at 25°C and 4°C, respectively. The concentrations of butorphanol tartrate and tropisetron hydrochloride remained greater than 98.0% in all admixtures. Additionally, there were no degradation
products of butorphanol and tropisetron hydrochloride detected in any of the admixtures. During our 14-day experiment, the pH value was close to pH 3.3 and changes were within 0.1 U of the initial pH for all drug mixtures.

**DISCUSSION**

Combinations of different drug solutions are often used in clinical practice to relieve postoperative pain with the PCA technique. However, little or no information is available regarding the chemical stability and compatibility of these analgesic mixtures. There are currently no commercially available analgesic mixtures, and the drugs must be prepared in the hospital pharmacy for clinical use. Thus, it is necessary to prove that drugs remain stable in admixture. Furthermore, it would be helpful if such combinations could be provided as ready-made mixtures to give greater assurance of sterility and

**TABLE 1. Validation of HPLC Method**

| Compound               | Measured Concentrations, mg/L | Accuracy, % | Precision RSD, % |
|------------------------|-------------------------------|-------------|------------------|
|                        |                               | Intraday    | Interday         |
| Butorphanol tartrate   | 40.0                          | 101.2       | 0.5              | 1.2              |
|                        | 80.0                          | 99.5        | 0.2              | 0.6              |
|                        | 120.0                         | 99.8        | 1.0              | 2.0              |
| Tropisetron hydrochloride | 25.0                         | 100.1       | 0.7              | 1.7              |
|                        | 50.0                          | 99.6        | 0.4              | 0.8              |
|                        | 75.0                          | 99.3        | 0.9              | 1.5              |

HPLC = high-pressure liquid chromatography, RSD = relative standard deviation.
is a strong acid–weak base salt (pKₐ 9.86 and is stable in weak acid solution (pH 3.0–5.5). Tropisetron hydrochloride, (1R,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1H-indole-3-carboxylate hydrochloride (1:1), is a strong acid–weak base salt (pKₐ 8.9). The solubility of tropisetron hydrochloride showed strong pH dependence, and the compound is stable in acid solution. Free tropisetron will precipitate in alkaline solution. The stability and compatibility tests of butorphanol tartrate alone or combined with other drugs in solution have demonstrated that butorphanol tartrate is a very stable drug. None of the previous tests have found any loss of butorphanol tartrate during the testing. The previous studies also reported that most of the tested drugs such as droperidol, perphenazine, tramadol, fentanyl, and ropivacaine were stable and compatible in the presence of butorphanol tartrate. However, in the case of lornoxicam or lansoprazole, free lornoxicam or lansoprazole was found to precipitate when combined with butorphanol tartrate. This result was most likely due to the acidic pH (3.0–5.5) of the butorphanol tartrate injection. There are 2 studies of tropisetron hydrochloride that assessed the stability and compatibility when diluted with either 0.9% sodium chloride or 5% dextrose and packaged in polyvinylchloride, polyolefin bags, and glass bottles. In both studies, tropisetron hydrochloride was stable for at least 14 days when stored at −20°C, 4°C, and 25°C. However, in a study with fosaprepitant admixtures, tropisetron hydrochloride was found to be physically incompatible with fosaprepitant because of its alkaline pH value.

In the present study, the pH of butorphanol tartrate–tropisetron hydrochloride mixtures was acidic and close to 3.3. However, there was no precipitation observed, and there was no modification of the chromatographic peaks when butorphanol tartrate was combined in solution with tropisetron hydrochloride. The stability and compatibility results showed that binary mixtures of butorphanol tartrate and tropisetron hydrochloride in 0.9% sodium chloride injection were stable for at least 14 days when stored in polyolefin bags and glass bottles at both 4°C and 25°C. It is important to note that drugs with pH-dependent incompatibility may present compatibility problems if combined or administered simultaneously with acidic drug solutions such as tropisetron hydrochloride or butorphanol tartrate.

### Table 2. Percentage of Initial Concentration (mean ± SD [%]; n = 3) of Butorphanol Tartrate (80 mg/L) and Tropisetron Hydrochloride (50 mg/L) Remaining After 14 d of Storage at 25°C in Polyolefin Bags or Glass Containers

| Variable                  | Glass Containers | Polyolefin Bags |
|---------------------------|------------------|-----------------|
| Study day                 | Butorphanol      | Tropisetron     | Butorphanol      | Tropisetron     |
|                           |                  |                 |                  |                 |
| 1                         | 81.03 ± 1.75     | 49.53 ± 0.81    | 81.19 ± 1.44     | 50.79 ± 0.21    |
| 2                         | 99.73 ± 1.52     | 99.83 ± 0.75    | 100.60 ± 0.16    | 99.88 ± 0.29    |
| 3                         | 98.68 ± 0.94     | 100.14 ± 1.12   | 100.55 ± 0.70    | 99.99 ± 0.11    |
| 5                         | 100.88 ± 0.42    | 100.63 ± 0.45   | 100.34 ± 1.01    | 99.81 ± 0.64    |
| 7                         | 98.72 ± 0.41     | 101.07 ± 0.85   | 100.82 ± 0.33    | 100.35 ± 0.55   |
| 10                        | 100.80 ± 0.95    | 100.68 ± 1.02   | 100.62 ± 0.98    | 99.91 ± 1.52    |
| 14                        | 100.53 ± 0.63    | 100.66 ± 0.62   | 99.98 ± 0.11     | 99.39 ± 0.63    |
|                           | 100.52 ± 0.18    | 100.76 ± 0.44   | 100.01 ± 0.66    | 99.60 ± 1.01    |

SD = standard deviation.

* n = 3.

### Table 3. Percentage of Initial Concentration (Mean ± SD [%]; n = 3) of Butorphanol Tartrate (80 mg/L) and Tropisetron Hydrochloride (50 mg/L) Remaining After 14 d of Storage at 4°C in Polyolefin Bags or Glass Containers

| Variable                  | Glass Containers | Polyolefin Bags |
|---------------------------|------------------|-----------------|
| Study day                 | Butorphanol      | Tropisetron     | Butorphanol      | Tropisetron     |
|                           |                  |                 |                  |                 |
| 1                         | 81.46 ± 1.21     | 51.33 ± 0.88    | 80.91 ± 0.95     | 51.09 ± 1.40    |
| 2                         | 100.29 ± 1.13    | 99.98 ± 0.20    | 100.18 ± 1.41    | 99.78 ± 1.70    |
| 3                         | 99.75 ± 0.69     | 99.87 ± 0.51    | 100.71 ± 0.79    | 100.27 ± 0.45   |
| 5                         | 98.48 ± 0.37     | 99.70 ± 0.56    | 100.52 ± 1.25    | 100.10 ± 1.25   |
| 7                         | 99.24 ± 0.83     | 100.26 ± 0.39   | 100.65 ± 0.74    | 99.32 ± 0.63    |
| 10                        | 100.47 ± 0.40    | 100.76 ± 0.51   | 100.90 ± 0.87    | 100.54 ± 0.17   |
| 14                        | 102.51 ± 1.05    | 102.42 ± 1.49   | 101.27 ± 0.32    | 100.96 ± 0.28   |
|                           | 100.41 ± 0.92    | 101.91 ± 1.22   | 99.68 ± 0.56     | 99.72 ± 0.84    |

SD = standard deviation.

* n = 3.
When mixing drugs taken from ampoules of sterile solutions, there is also the potential issue of bacterial contamination. We have examined the physicochemical stability without examining microbial contamination. In clinical practice it is necessary to follow Chapter 797 of the United States Pharmacopeia (USP)/National Formulary. This regulation describes the compounding preparation of low-risk sterile products. To ensure drug safety, the preparation should not be used for more than 48 hours after the date at room temperature or 14 days at refrigerated temperatures according to USP specifications.

CONCLUSION

In summary, a reliable analytical HPLC method for the simultaneous determination of butorphanol tartrate and tropisetron hydrochloride in analgesic mixture samples was successfully developed. This method was used to study the stability of the drug mixture at the usual concentration levels used in PCA. The results of the stability study showed that mixtures of butorphanol tartrate 0.08 mg/mL and tropisetron hydrochloride 0.05 mg/mL in 0.9% sodium chloride injection were stable for at least 14 days when stored in polyolefin bags or glass bottles at 4°C and 25°C and protected from light.

REFERENCES

1. Gikut M, Di Paolo ER, Pannatier A, et al. Evaluation of physico-chemical incompatibilities during parenteral drug administration in a paediatric intensive care unit. Pharm World Sci. 2000;22:88–91.
2. Trissel LA. Handbook on Injectable Drugs. 16th ed. Bethesda: American Society of Health-System Pharmacists; 2011.
3. Wang F, Shen X, Liu Y, et al. Continuous infusion of butorphanol combined with intravenous morphine patient-controlled analgesia after total abdominal hysterectomy: a randomized, double-blind controlled trial. Eur J Anaesthesiol. 2009;26:28–34.
4. Commiskey S, Fan LW, Ho IK, et al. Butorphanol: effects of a prototypical agonist–antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005;98:109–116.
5. Wermeling DP, Foster TS, Farrington EA, et al. Patient-controlled analgesia using butorphanol for postoperative pain relief: an open-label study. Acute Care. 1998;12:31–39.
6. Apfel CC, Heidrich FM, Jakar-Rao S, et al. Evidence-based analysis of risk factors for postoperative nausea and vomiting. Br J Anaesth. 2012;109:742–753.
7. Boogaerts JG, Bardiau FM, Seidel L, et al. Tropisetron in the prevention of postoperative nausea and vomiting. J Clin Anesth. 2000;12:402–408.
8. Kranke P, Eberhart LH, Apfel CC, et al. Tropisetron for prevention of postoperative nausea and vomiting: a quantitative systematic review. Anaesthesia. 2002;57:805–814.
9. Jiang LH, Zhang W, Wang J, et al. Effective comparison of three kinds of analgesics used in intravenous analgesia after cesarean section. Chin J Clin. 2013;7:10466–10471.
10. Chu JH, Yan RL. Application of butorphanol combined with tropisetron in intravenous analgesia treating cancer pain before dying. Mod Diagn Treat. 2012;23:2088–2089.
11. Trissel LA, Trusty C, Ben M, et al. Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration. Am J Health Syst Pharm. 2007;64:1209–1213.
12. Bougué C, Theclie C, Crespin-Maillard F, et al. Compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in multilayer polyolefin containers. Am J Health Syst Pharm. 2005;62:2001–2005.
13. McIntosh D, Spaven J, Hagen NA. How long do prepared epidural solutions remain sterile? J Pain Symptom Manage. 1999;18:137–139.
14. Sánchez del Aguila MJ, Jones MF, Vohra A. Premixed solutions of diamorphine in ropivacaine for epidural anaesthesia: a study on their long-term stability. Br J Anaesth. 2003;90:179–182.
15. Tzvetkov MV, Saadatmand AR, Bokelmann K, et al. Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J. 2012;12:22–29.
16. Chen FC, Fang BX, Li P, et al. Study on the stability of butorphanol tartrate injection in 0.9% sodium chloride injection. Chin Pharm. 2012;15:1618–1620.
17. Chen FC, Fang BX, Li P, et al. Compatibility of butorphanol and droperidol in 0.9% sodium chloride injection. Am J Health Syst Pharm. 2013;70:515–519.
18. Parker WA. Compatibility of perphenazine and butorphanol admixtures. Can J Hosp Pharm. 1980;33:152.
19. Chen FC, Fang BX, Li P, et al. Physico-chemical stability of butorphanol–tramadol and butorphanol–fentanyl patient-controlled analgesia infusion solutions over 168 hours. Pharmazie. 2014;69:585–588.
20. Chen FC, Li P, Zhou BH, et al. Stability of an epidural analgesic admixture containing butorphanol tartrate and ropivacaine hydrochloride. Eur J Hosp Pharm. 2015;22:7–11.
21. Fang BX, Zhu J, Chen FC, et al. Stability of butorphanol tartrate injection with lornoxicam injection in patient controlled analgesia pump. Cent South Pharm. 2013;11:732–734.
22. Trissel LA, Saenz C, Williams YW, et al. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compd. 2001;5:314–321.
23. Georget S, Vigneron J, Blaise N, et al. Stability of refrigerated and frozen solutions of tropisetron in either polyvinylchloride or polyolefin infusion bags. J Clin Pharm Ther. 1997;22:257–260.
24. Brigas F, Sautou-Miranda V, Normand B, et al. Compatibility of tropisetron with glass and plastics. Stability under different storage conditions. J Pharm Pharmacol. 1998;50:407–411.
25. Sun S, Schaller J, Placek J, et al. Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids. Cancer Chemother Pharmacol. 2013;72:509–513.
26. Kastango ES, Bradshaw BD. USP chapter 797: establishing a practice standard for compounding sterile preparations in pharmacy. Am J Health Syst Pharm. 2004;61:1928–1938.
27. Trissel LA. The new national standard for sterile preparation. Hosp Pharm. 2004;39:900–904.